GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (ASX:CUV) » Definitions » Cash Receipts from Tax Refunds

Clinuvel Pharmaceuticals (ASX:CUV) Cash Receipts from Tax Refunds


View and export this data going back to 2001. Start your Free Trial

What is Clinuvel Pharmaceuticals Cash Receipts from Tax Refunds?

Cash Receipts from Tax Refunds only applies to banks and insurance companies.


Clinuvel Pharmaceuticals (ASX:CUV) Business Description

Traded in Other Exchanges
Address
535 Bourke Street, Level 11, Melbourne, VIC, AUS, 3000
Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.